Blocking SIRT2 Enzyme Shows Promise as Potential CMT2D Therapy

Blocking SIRT2 Enzyme Shows Promise as Potential CMT2D Therapy

298657

Blocking SIRT2 Enzyme Shows Promise as Potential CMT2D Therapy

Mutations in the GARS protein — found in people with Charcot-Marie-Tooth disease type 2D (CMT2D) — enhanced the activity of the enzyme SIRT2, and led to motor deficits and other alterations in fruit flies, a study has found. In turn, blocking the action of SIRT2 rescued motor deficits, supporting its potential as a therapeutic target to treat CMT2D.  The study, “SIRT2-knockdown rescues GARS-induced Charcot-Marie-Tooth neuropathy,” was published in the journal Aging Cell.  CMT2 is caused…

You must be logged in to read/download the full post.